ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $31.94 billion. The enterprise value is $31.54 billion.
| Market Cap | 31.94B |
| Enterprise Value | 31.54B |
Important Dates
The last earnings date was Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Nov 12, 2026 |
Share Statistics
ResMed has 140.66 million shares outstanding. The number of shares has decreased by -1.35% in one year.
| Current Share Class | 140.66M |
| Shares Outstanding | 140.66M |
| Shares Change (YoY) | -1.35% |
| Shares Change (QoQ) | -1.08% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 80.57% |
| Float | 139.83M |
Valuation Ratios
The trailing PE ratio is 20.68 and the forward PE ratio is 18.34. ResMed's PEG ratio is 2.26.
| PE Ratio | 20.68 |
| Forward PE | 18.34 |
| PS Ratio | 5.57 |
| Forward PS | 5.43 |
| PB Ratio | 5.37 |
| P/TBV Ratio | 12.30 |
| P/FCF Ratio | 19.85 |
| P/OCF Ratio | 18.04 |
| PEG Ratio | 2.26 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.83, with an EV/FCF ratio of 19.60.
| EV / Earnings | 19.80 |
| EV / Sales | 5.50 |
| EV / EBITDA | 14.83 |
| EV / EBIT | 16.17 |
| EV / FCF | 19.60 |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.65 |
| Quick Ratio | 1.54 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | 0.38 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 26.40% and return on invested capital (ROIC) is 26.88%.
| Return on Equity (ROE) | 26.40% |
| Return on Assets (ROA) | 14.76% |
| Return on Invested Capital (ROIC) | 26.88% |
| Return on Capital Employed (ROCE) | 28.32% |
| Weighted Average Cost of Capital (WACC) | 8.29% |
| Revenue Per Employee | $504,193 |
| Profits Per Employee | $140,120 |
| Employee Count | 11,370 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.16 |
Taxes
In the past 12 months, ResMed has paid $418.61 million in taxes.
| Income Tax | 418.61M |
| Effective Tax Rate | 20.81% |
Stock Price Statistics
The stock price has decreased by -8.02% in the last 52 weeks. The beta is 0.76, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -8.02% |
| 50-Day Moving Average | 231.72 |
| 200-Day Moving Average | 224.59 |
| Relative Strength Index (RSI) | 40.26 |
| Average Volume (20 Days) | 1,333,173 |
Short Selling Information
The latest short interest is 11.92 million, so 8.47% of the outstanding shares have been sold short.
| Short Interest | 11.92M |
| Short Previous Month | 14.20M |
| Short % of Shares Out | 8.47% |
| Short % of Float | 8.52% |
| Short Ratio (days to cover) | 10.34 |
Income Statement
In the last 12 months, ResMed had revenue of $5.73 billion and earned $1.59 billion in profits. Earnings per share was $10.98.
| Revenue | 5.73B |
| Gross Profit | 3.54B |
| Operating Income | 1.95B |
| Pretax Income | 2.01B |
| Net Income | 1.59B |
| EBITDA | 2.13B |
| EBIT | 1.95B |
| Earnings Per Share (EPS) | $10.98 |
Balance Sheet
The company has $1.01 billion in cash and $610.58 million in debt, with a net cash position of $400.16 million or $2.84 per share.
| Cash & Cash Equivalents | 1.01B |
| Total Debt | 610.58M |
| Net Cash | 400.16M |
| Net Cash Per Share | $2.84 |
| Equity (Book Value) | 5.95B |
| Book Value Per Share | 42.29 |
| Working Capital | 2.18B |
Cash Flow
In the last 12 months, operating cash flow was $1.77 billion and capital expenditures -$162.06 million, giving a free cash flow of $1.61 billion.
| Operating Cash Flow | 1.77B |
| Capital Expenditures | -162.06M |
| Depreciation & Amortization | 176.27M |
| Net Borrowing | -260.00M |
| Free Cash Flow | 1.61B |
| FCF Per Share | $11.44 |
Margins
Gross margin is 61.77%, with operating and profit margins of 34.02% and 27.79%.
| Gross Margin | 61.77% |
| Operating Margin | 34.02% |
| Pretax Margin | 35.09% |
| Profit Margin | 27.79% |
| EBITDA Margin | 37.09% |
| EBIT Margin | 34.02% |
| FCF Margin | 28.06% |
Dividends & Yields
This stock pays an annual dividend of $2.64, which amounts to a dividend yield of 1.16%.
| Dividend Per Share | $2.64 |
| Dividend Yield | 1.16% |
| Dividend Growth (YoY) | 11.50% |
| Years of Dividend Growth | 13 |
| Payout Ratio | 24.05% |
| FCF Payout Ratio | 23.08% |
| Buyback Yield | 1.35% |
| Shareholder Yield | 2.51% |
| Earnings Yield | 4.83% |
| FCF Yield | 5.04% |
Analyst Forecast
The average price target for ResMed is $265.11, which is 16.75% higher than the current price. The consensus rating is "Buy".
| Price Target | $265.11 |
| Price Target Difference | 16.75% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 5.29% |
| EPS Growth Forecast (3Y) | 9.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.04 and a Piotroski F-Score of 7.
| Altman Z-Score | 12.04 |
| Piotroski F-Score | 7 |